Multiple Sclerosis Clinical Trial
A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis
This is a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.
The study will aim to enroll ninety-four (94) patients/care partners. The time period for enrollment is dependent on the uptake of KESIMPTA in the real-world.
Data collected for the study will be obtained directly from the patient/care partner within the web-based database: De-identified data will be stored on a secure server and transferred for analysis. Responses from the patient and care partner surveys will be pooled for analysis of study endpoints.
Patients with MS Inclusion Criteria:
Adult aged eighteen (18) years of age or over at the time of the survey
Prescribed KESIMPTA within the prior 12 months and currently self-administering treatment using the Sensoready® pen
MS diagnosis based on 2017 McDonald criteria
Care Partner Inclusion Criteria:
Adult aged eighteen (18) years of age or over
Formal or informal care partner of patient with MS prescribed KESIMPTA within the prior 12 months
Is currently administering KESIMPTA using the Sensoready® pen on their patient's behalf
Patients with MS Exclusion Criteria:
Previously used injection as a part of inclusion in any ofatumumab (OMB) randomized clinical trial
Active Hepatitis B virus (HBV)
Cognitive impairment that would impact their ability to participate in a survey study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
East Hanover New Jersey, 07936, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.